Duloxetine
ApprovedUNKNOWN 0 views this week 0 watching💤 Quiet
Interest: 39/100
39
Development Stage
✓
Pre-clinical✓
Phase 1✓
Phase 2✓
Phase 35
ApprovedIndication / Disease
Major Depressive Disorder
Conditions
Major Depressive Disorder
Trial Timeline
May 1, 2009 → Jun 1, 2012
NCT ID
NCT00889369About Duloxetine
Duloxetine is a approved stage product being developed by Eli Lilly for Major Depressive Disorder. The current trial status is unknown. This product is registered under clinical trial identifier NCT00889369. Target conditions include Major Depressive Disorder.
What happened to similar drugs?
20 of 20 similar drugs in Major Depressive Disorder were approved
Approved (20) Terminated (0) Active (0)
Hype Score Breakdown
Clinical
20
Activity
4
Company
15
Novelty
0
Community
0
Clinical Trials (20)
| NCT ID | Phase | Status |
|---|---|---|
| NCT01391221 | Approved | UNKNOWN |
| NCT01363284 | Pre-clinical | Completed |
| NCT01089621 | Approved | Withdrawn |
| NCT01051466 | Approved | Completed |
| NCT00989157 | Phase 3 | Completed |
| NCT01074151 | Pre-clinical | Completed |
| NCT00889369 | Approved | UNKNOWN |
| NCT01754493 | Approved | Completed |
| NCT01028352 | Pre-clinical | Completed |
| NCT00696774 | Approved | Completed |
| NCT00532480 | Approved | Completed |
| NCT00529789 | Phase 2 | Completed |
| NCT00696293 | Approved | Completed |
| NCT00517985 | Approved | Completed |
| NCT00398632 | Approved | Terminated |
| NCT00401258 | Approved | Completed |
| NCT00438971 | Approved | Completed |
| NCT00531895 | Approved | Completed |
| NCT00322621 | Approved | Completed |
| NCT01035073 | Approved | Completed |
Competing Products
20 competing products in Major Depressive Disorder
| Product | Company | Stage | Hype Score |
|---|---|---|---|
| Duloxetine Hydrochloride | Eli Lilly | Pre-clinical | 26 |
| LY2216684 | Eli Lilly | Phase 1 | 29 |
| LY2216684 | Eli Lilly | Phase 1 | 29 |
| Duloxetine | Eli Lilly | Phase 3 | 40 |
| LY2216684 + Digoxin | Eli Lilly | Phase 1 | 29 |
| Duloxetine + Paroxetine | Eli Lilly | Phase 3 | 40 |
| Duloxetine + placebo | Eli Lilly | Phase 3 | 40 |
| LY2216684 + Placebo + Escitalopram | Eli Lilly | Phase 2 | 35 |
| FK949E | Astellas Pharma | Phase 1 | 29 |
| quetiapine extended release (XR) + Placebo | Astellas Pharma | Phase 2 | 35 |
| FK949E | Astellas Pharma | Phase 1 | 29 |
| FK949E | Astellas Pharma | Phase 1 | 29 |
| FK949E | Astellas Pharma | Phase 1 | 29 |
| Mirtazapine Tablets | Sun Pharmaceutical | Approved | 43 |
| ONO-2333Ms Experimental 2 + Placebo + ONO-2333Ms Experimental 1 | Ono Pharmaceutical | Phase 2 | 35 |
| ONO-1110 + Placebo | Ono Pharmaceutical | Phase 2 | 39 |
| Pramipexole ER + Escitalopram | Cipla | Phase 2 | 42 |
| LY2216684 + Sertraline | Eli Lilly | Phase 1 | 29 |
| LY2216684 + Placebo + Lorazepam | Eli Lilly | Phase 1 | 29 |
| LY2216684 + SSRI | Eli Lilly | Phase 3 | 40 |